Lexaria Bioscience (LEXX) Change in Receivables (2010 - 2026)
Lexaria Bioscience's (LEXX) quarterly Change in Receivables came in at -$46015.0 in Q1 2026, down 168.0% year-on-year from $67674.0 in Q1 2025, and up 83.58% quarter-over-quarter from -$280314.0 in Q4 2025.
Lexaria Bioscience (LEXX) Change in Receivables (2010 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Change in Receivables across 17 years of filings, most recently posting -$46015.0 for Q1 2026.
- Change in Receivables for Q1 2026 came in at -$46015.0, down 168.0% year-over-year; the trailing twelve-month figure through Feb 2026 was -$289136.0 (down 1491.72% YoY), and the FY2025 annual result was $213881.0, up 501.62% from the prior year.
- Change in Receivables came in at -$46015.0 for Q1 2026 at Lexaria Bioscience, up from -$280314.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $408045.0 in Q4 2023 to a low of -$280314.0 in Q4 2025.
- The 5-year median for Change in Receivables is -$19550.0 (2023), against an average of -$19617.6.
- Across the five-year window, Change in Receivables soared 382.68% in 2023 and slumped 808.65% in 2024, its largest moves.
- Lexaria Bioscience's Change in Receivables stood at $84538.0 in 2022, then jumped by 382.68% to $408045.0 in 2023, then plunged by 73.28% to $109014.0 in 2024, then sank by 357.14% to -$280314.0 in 2025, then jumped by 83.58% to -$46015.0 in 2026.
- The last three Change in Receivables figures came in at -$46015.0 (Q1 2026), -$280314.0 (Q4 2025), and $10229.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -4.08 Mn |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | -46,015.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -46,015.00 |
| Feb 28, 2026 | -46,015.00 |
| Nov 30, 2025 | -280,314.00 |
| Nov 30, 2025 | -280,314.00 |
| Aug 31, 2025 | 10,229.00 |
| Aug 31, 2025 | 10,229.00 |
| May 31, 2025 | 26,964.00 |
| May 31, 2025 | 26,964.00 |
| Feb 28, 2025 | 67,674.00 |
| Feb 28, 2025 | 67,674.00 |
| Nov 30, 2024 | 109,014.00 |
| Nov 30, 2024 | 109,014.00 |
| Aug 31, 2024 | -46,208.00 |
| Aug 31, 2024 | -46,208.00 |
| May 31, 2024 | -148,645.00 |
| May 31, 2024 | -148,645.00 |
| Feb 29, 2024 | -177,641.00 |
| Feb 29, 2024 | -177,641.00 |
| Nov 30, 2023 | 408,045.00 |
| Nov 30, 2023 | 408,045.00 |